Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Penumbra, Inc. has entered into a definitive agreement to be acquired by Boston Scientific Corporation, with the transaction expected to close in 2026, subject to customary conditions and approvals. Company leaders tell customers, distributors, suppliers and clinical study partners that Penumbra and Boston Scientific will operate independently until closing and that Penumbra’s products, contracts, commitments and clinical trials are expected to continue without change during this period. The messages emphasize ongoing focus on product excellence, innovation and global patient access. Investors are told that Boston Scientific will file a Form S-4 registration statement containing a joint proxy statement/prospectus, and that stockholders should carefully read those materials when available, as well as the detailed risk factors and forward-looking statement disclosures related to the proposed merger.
Boston Scientific plans to acquire Penumbra for $374 per share in a cash‑and‑stock deal valuing Penumbra at $15 billion. The consideration mix is about $11 billion in cash and $4 billion in Boston Scientific stock, with roughly 41 million new Boston Scientific shares issued, and closing targeted in 2026 subject to customary conditions.
Penumbra expects strong 2025 results, with preliminary Q4 2025 revenue growth of 21.4%–22% and full‑year revenue of about $1.4 billion, up roughly 17.3%–17.5%. Boston Scientific highlights Penumbra’s presence in high‑growth mechanical thrombectomy and neurovascular markets and plans to run Penumbra largely as a standalone business within its cardiovascular group while leveraging its global commercial and manufacturing footprint.
Financially, Boston Scientific projects the deal will be slightly dilutive to adjusted EPS in the first full year post‑close by $0.06–$0.08, turning slightly accretive in year two and increasingly accretive after achieving over $200 million of operating income impact from revenue synergies and cost efficiencies in year three. Management reiterates its goals for double‑digit EPS growth and long‑term margin expansion over 2026–2028.
Boston Scientific agreed to acquire Penumbra, Inc. through a merger where each Penumbra share will be converted, at the holder’s election and subject to proration, into either $374.00 in cash or 3.8721 Boston Scientific shares. Overall, 73.26% of Penumbra shares are expected to receive cash and 26.74% stock, with Penumbra becoming a wholly owned subsidiary of Boston Scientific if the deal closes. Completion depends on Penumbra stockholder approval, required regulatory clearances (including antitrust reviews), effectiveness of a Form S-4, and New York Stock Exchange listing of the new Boston Scientific shares, along with other customary conditions. The agreement includes a $525 million termination fee payable by Penumbra in certain competing-deal scenarios and a $900 million reverse termination fee payable by Boston Scientific if specified regulatory conditions are not met despite other closing conditions being satisfied.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation. Penumbra stockholders, including employees, are expected to receive $374 per share of Penumbra common stock in a mix of cash and Boston Scientific stock.
The transaction is expected to close in 2026, subject to Penumbra stockholder approval, required regulatory approvals and other customary closing conditions. After closing, Penumbra will become a standalone group within Boston Scientific, and Penumbra’s CEO is expected to join the Boston Scientific board.
Penumbra tells employees there are no immediate changes to day-to-day roles or reporting. Unvested restricted stock units are expected to vest at closing and convert into the same cash/stock mix, and existing employee stock purchase plans will continue through the current purchase period.
Boston Scientific Corporation has executed a definitive agreement to acquire Penumbra, Inc., with the transaction subject to specified terms and closing conditions in the merger agreement. The companies issued a joint press release and Boston Scientific scheduled a same-day conference call and posted an investor presentation to explain the proposed acquisition and its expected impact.
The report emphasizes that many statements about the transaction, its benefits, timing, integration, and future financial and business performance are forward-looking and subject to numerous economic, regulatory, operational, and integration risks, including required regulatory approvals and the possibility the transaction may be delayed or not close. Boston Scientific will file a Form S-4 with a joint proxy statement/prospectus so Penumbra stockholders can review detailed terms before voting.
Penumbra, Inc. has agreed to be acquired by Boston Scientific Corporation in a cash-and-stock merger, after which Penumbra will become a wholly owned subsidiary and its shares will be delisted from the NYSE. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock. The deal requires approval by Penumbra stockholders, antitrust clearances in the U.S. and other jurisdictions, an effective Form S-4 for Boston Scientific shares, and NYSE listing approval for those shares. The merger agreement includes a $525 million termination fee payable by Penumbra in certain circumstances and a $900 million reverse termination fee payable by Boston Scientific if antitrust-related conditions are not met despite other conditions being satisfied.
Penumbra, Inc. agreed to be acquired by Boston Scientific Corporation through a cash-and-stock merger where Penumbra will become a wholly owned subsidiary. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific common shares, with elections subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock.
The deal requires approval by a majority of Penumbra’s voting shares, antitrust and other regulatory clearances, effectiveness of Boston Scientific’s Form S-4, and NYSE listing approval for the stock consideration. Either side may owe a termination fee under certain conditions, including $525 million payable by Penumbra and $900 million payable by Boston Scientific if specified antitrust-related conditions are not met. If the merger closes, Penumbra’s stock will be delisted and deregistered, and the companies have issued and plan further SEC filings and proxy materials describing the transaction.
Penumbra Inc. director Harpreet Grewal reported a small insider sale of common stock. On January 6, 2026, Grewal sold 186 shares of Penumbra common stock at a price of $312.64 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Grewal directly beneficially owned 8,230 shares of Penumbra common stock.
Penumbra Inc. director Thomas C. Wilder reported a small sale of company stock. On 01/02/2026, he sold 186 shares of Penumbra common stock at a price of $310.72 per share, coded as a sale transaction. Following this trade, he no longer holds shares directly but continues to beneficially own 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
The filing notes that the sale was carried out under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.